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Abstract: Mitochondrial misreading, conferred by mutation V338Y in mitoribosomal protein Mrps5,
in-vivo is associated with a subtle neurological phenotype. Brain mitochondria of homozygous knock-
in mutant Mrps5V338Y/V338Y mice show decreased oxygen consumption and reduced ATP levels.
Using a combination of unbiased RNA-Seq with untargeted metabolomics, we here demonstrate a
concerted response, which alleviates the impaired functionality of OXPHOS complexes in Mrps5
mutant mice. This concerted response mitigates the age-associated decline in mitochondrial gene
expression and compensates for impaired respiration by transcriptional upregulation of OXPHOS
components together with anaplerotic replenishment of the TCA cycle (pyruvate, 2-ketoglutarate).
Keywords: mitochondria; misreading; brain; aging; metabolome
1. Introduction
Mitochondria are multi-functional organelles involved in oxidative metabolism, cellu-
lar homeostasis, and signal transduction [1–3]. As the site of oxidative phosphorylation,
mitochondria convert the energy from nutrients into ATP. To perform their key role in
cellular energy production, mitochondria use intricate systems that encompass the break-
down of glucose and fatty acids, coupled to oxidative phosphorylation via the citrate
cycle (TCA) [4,5]. Mitochondrial diseases are clinically diverse and may manifest in a
tissue-specific or multisystemic manner. Most often they affect postmitotic tissues with
high energy demands such as brain, skeletal muscle, heart, or cochlea [6–8].
The vast majority of proteins essential for mitochondrial function are nuclear encoded;
only 13 of the more than 100 different proteins that make up the mitochondrial oxidative
system are encoded by mitochondrial DNA and translated by the mitoribosome [9,10].
The amino acid (aa) replacement V338Y in mouse mitoribosomal protein Mrps5 (uS5) is a
recently identified ribosomal ambiguity mutation (ram), which decreases translational accu-
racy and confers mitoribosomal misreading by increasing the incorporation of near-cognate
aa-tRNA species [11]. Despite the universal presence of mitochondria, homozygous knock-
in C57/BL6 mice carrying the Mrps5 V338Y mutation display a remarkable absence of
overt pathology in vivo. The phenotype presented by mutant MRPS5V338Y/V338Y mice is
subtle and mainly composed of neurological stress intolerance and anxiety-related behav-
ioral alterations [11]. Brain mitochondria from MRPS5V338Y/V338Y mice show impaired
mitochondrial function, as revealed by a decline in total oxygen consumption rate (OCR),
reduced levels of ATP, and increased amounts of mitochondrial reactive oxygen species
(mtROS) [11].
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To further assess the alterations induced by mitochondrial misreading in brain of
MRPS5V338Y/V338Y mutant mice at the molecular level, we here used unbiased whole
genome RNA-Seq combined with metabolome analysis. For profiling, wild-type and
V338Y mutant female mice were sampled at three and 19 months of age for investigations
at transcriptome level, together with metabolome studies at 19 months of age.
2. Results
2.1. Transcriptome Sequencing and Age-Related Changes
Transcriptomes of total cortex tissue samples from wild-type and MRPS5V338Y/V338Y
mutant mice were resolved using RNA-Seq. A total of 16 samples (four for each time-point
and genotype) were sequenced. Differential gene expression analysis showed significant
transcriptomic changes between young (three months) and old (19 months) animal brain
samples. With a threshold p-value < 0.05, there were 10,914 and 9355 age-regulated
transcripts in wild-type and mutant V338Y datasets, respectively (Supplementary Table
S1). Differentially expressed genes (DEGs) with a p-value < 1 × 10−5 (FDR < 7.31 × 10−5),
subjected to gene enrichment analysis using online tools EnrichR (https://maayanlab.
cloud/Enrichr/ accessed on 8 June 2020) [12] and MetaCore (https://portal.genego.com/
accessed on 8 June 2020), revealed the characteristic age-related changes in both wild-type
and V338Y mutant animals [13,14].
Thus, many cellular metabolic processes declined with aging in our mouse cohorts:
most prominently mitochondria-related energy production [15,16] (KEGG: oxidative phos-
phorylation, thermogenesis, citrate cycle, pyruvate metabolism; Wiki: electron transport
chain, glycolysis), but also RNA metabolism (KEGG: RNA transport; Wiki: mRNA process-
ing; PN: transcription/transcription by RNA polymerase II), translation (Wiki: translation
factors), protein degradation (KEGG: proteasome, ubiquitin-mediated proteolysis; GO:
protein polyubiquitination), and synapse-related functions (KEGG: synaptic vesicle cycle,
dopaminergic synapse, cholinergic synapse, GABAergic synapse; PN: neurophysiological
process/transmission of nerve impulse, development/neurogenesis/synaptogenesis). Up-
regulated pathways in the aging brain of our mouse cohorts were mostly connected to extra-
cellular matrix reorganization (KEGG: ECM-receptor interaction, cell adhesion molecules;
Wiki: focal adhesion; GO: extracellular matrix organization; PN: cell adhesion/cell-matrix
interactions) and inflammation (KEGG: complement and coagulation cascade; Wiki: inflam-
matory response pathway; GO: neutrophil mediated immunity) (Supplementary Figure S1).
2.2. Mutation-Related Transcriptome Changes in 19-Month-Old Animals
For a further assessment of differences, we performed a between group analysis
(BGA). BGA simplifies a dataset by reducing its dimensionality and defining axes that best
discriminate the groups. We plotted the four groups (three-month-old wild-type, three-
month-old V338Y, 19-month-old wild-type, 19-month-old V338Y) into two-dimensional
space using the first two most important axes. BGA showed a similar pattern for wild-type
and V338Y mutant animals at three months of age. At 19 months of age, the transcriptomic
profiles of both genotypes were significantly different from the three-month-old animals.
In addition, the 19-month-old V338Y mice were distinct from the age-matched controls,
indicating that both age and genotype contribute to the transcriptomic changes. As the
three-month- and 19-month-old animals were separated along axis 1 of the scatter plot
(Figure 1A), we conclude that axis 1 captures the largest fraction of age-related variance,
and thus represents aging, while axis 2 most likely captures the changes associated with the
second variable in this group of animals, the genotype, and thus represents the mutation
effect (p-value 19-month-old V338Y/19 months wt: 1.4 × 10−5).
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Figure 1. Brain transcriptome analysis. (A) Between group analysis (BGA) scatter plot for brain transcriptome profiles (n = 4
for three months old MRPS5 WT—brown; n = 4 for three-month-old MRPS5 V338Y—green; n = 4 for 19-month-old MRPS5
WT—blue; n = 4 for 19-month-old MRPS5 V338Y—red; NS—not significant). (B) Gene enrichment analysis comparing
19-month old MRPS5 V338Y and MRPS5 WT mice, terms and significance for selected upregulated gene transcripts in
mutants, adjusted p-values are shown.
Direct comparison of 19-month-old wild-type and V338Y mutant animals revealed
1761 differentially regulated genes at p-value < 0.01 (FDR < 0.09) (see Supplementary
Table S1C). Subjecting those DEGs to pathway analysis revealed that the most prominent
terms upregulated in V338Y mutants relative to wild-type were mitochondria-related, i.e.,
oxidative phosphorylation, electron transport chain, mitochondrial transport, pyruvate
metabolism, citrate cycle, and glycolysis (see Figure 1).
Compared to 19-month-old wild-type mice, a large number of OXPHOS-related genes
showed significantly increased transcript levels in the 19-month-old V338Y mutants, as
did key enzymes of the citrate cycle (see heatmaps Figure 2 and Table 1 for individual
genes), e.g., isocitrate dehydrogenase complex subunits Idh3b and Idh3g, which catalyze
irreversible rate-limiting steps, malate dehydrogenase (Mdh2), oxoglutarate dehydrogenase
(Ogdh1, Dld), succinate-CoA ligase (Sucla2), succinate dehydrogenase (Sdhb), and fumarate
hydratase (Fh1).
Transcriptional activation of the citrate cycle came along with significantly increased
transcript levels for key enzymes of glycolysis, e.g., hexokinase 1 (Hk1), phosphofructoki-
nases (Pfk1, Pfkm), phosphoglycerate kinase 1 (Pgk1), and pyruvate kinase (Pkm). Increased
transcript levels for the mitochondrial pyruvate carrier MPC1 and MPC2 indicate that the
excess of pyruvate derived from glycolysis is transported into the mitochondria, where
it enters the TCA either as acetyl-CoA (Pdp1, Dlat, Dld) or as anaplerotic replenishment
by means of pyruvate carboxylase (Pcx), which catalyzes the transformation of pyruvate
to oxaloacetate. Additional anaplerotic replenishment of the TCA by α-ketoglutarate is
indicated by increased transcript levels of Gls2 and Got2 (see Figure 3).















Figure 2. Brain transcriptome analysis. Heatmaps of the genes involved in the mitochondria-associated pathways, regulated
in brain of 19-month-old MRPS5 V338Y mutant mice, p-value < 0.05. Please note the different scales for aging and
mutation effect.
Table 1. Regulated genes related to mitochondria-associated metabolism in 19-month-old MRPS5V338Y/V338Y mutant
compared to wild-type mice.
Gene Name Fold Change p-Value
Glycolysis
hexokinase 1 Hk1 1.07 2.09 × 10−2
hexokinase 3 Hk3 0.79 2.41 × 10−2
phosphofructokinase, liver, B-type Pfkl 1.09 5.27 × 10−3
phosphofructokinase, muscle Pfkm 1.08 1.22 × 10−2
triosephosphate isomerase 1 Tpi1 1.09 6.05 × 10−3
phosphoglycerate kinase 1 Pgk1 1.08 1.24 × 10−2
phosphoglycerate mutase 1 Pgam1 1.10 9.78 × 10−3
enolase 2 Eno2 1.12 2.63 × 10−4
pyruvate kinase, muscle Pkm 1.10 3.32 × 10−3
lactate dehydrogenase B Ldhb 1.07 2.75 × 10−2
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Table 1. Cont.
Gene Name Fold Change p-Value
Mitochondrial transporters
mitochondrial pyruvate carrier 1 Mpc1 1.19 2.42 × 10−5
mitochondrial pyruvate carrier 2 Mpc2 1.08 3.99 × 10−2
solute carrier family 25 member 4 (mitochondrial
ATP/ADP translocator)
Slc25a4 1.10 2.70 × 10−3
solute carrier family 25 member 12 (mitochondrial
aspartate/glutamate antiporter Aralar)
Slc25a12 1.07 2.54 × 10−2
TCA and related processes
dihydrolipoamide S-acetyltransferase (component of
pyruvate dehydrogenase complex)
Dlat 1.07 4.00 × 10−2
dihydrolipoamide dehydrogenase Dld 1.16 1.17 × 10−5
pyruvate dehyrogenase phosphatase catalytic subunit 1 Pdp1 1.08 1.73 × 10−2
isocitrate dehydrogenase 3 (NAD+), gamma Idh3g 1.10 4.79 × 10−3
isocitrate dehydrogenase 3 (NAD+) beta Idh3b 1.07 2.53 × 10−2
malate dehydrogenase 1, NAD (cytosolic) Mdh1 1.13 1.42 × 10−4
malate dehydrogenase 2, NAD (mitochondrial) Mdh2 1.08 8.42 × 10−3
oxoglutarate dehydrogenase-like (mitochondrial) Ogdhl 1.10 1.56 × 10−3
succinate-Coenzyme A ligase, ADP-forming, beta subunit Sucla2 1.07 2.56 × 10−2
succinate dehydrogenase complex, subunit B Sdhb 1.07 3.86 × 10−2
fumarate hydratase 1 Fh1 1.08 3.16 × 10−2
glutamate oxaloacetate transaminase 2 (mitochondrial) Got2 1.13 1.05 × 10−4
ATP citrate lyase Acly 1.09 4.38 × 10−3
acetyl-Coenzyme A carboxylase beta Acacb 1.23 4.84 × 10−5
Fatty acid transport and degradation
carnitine palmitoyltransferase 1a, liver Cpt1a 0.90 2.77 × 10−3
acyl-CoA synthetase family member 2 Acsf2 0.80 1.61 × 10−3
acyl-CoA synthetase short-chain family member 3 Acss3 0.82 3.30 × 10−2
acyl-CoA synthetase short-chain family member 1 Acss1 0.91 4.41 × 10−2
2,4-dienoyl CoA reductase 1, mitochondrial Decr1 0.89 1.20 × 10−2
Glutathione metabolism and ROS
glutathione S-transferase, mu7 Gstm7 1.15 2.43 × 10−2
glutathione peroxidase 4 Gpx4 1.07 3.82 × 10−2
superoxide dismutase 1, cytosolic Sod1 1.07 3.84 × 10−2
peroxiredoxin 5 Prdx5 1.17 1.32 × 10−6
peroxiredoxin 2 Prdx2 1.09 5.83 × 10−3
Only genes with a p-value ≤ 0.05 are shown.





Figure 3. Scheme of the mitochondria-associated metabolic pathways affected in mouse brain by mutation MRPS5 V338Y.
In contrast to the increased flow through TCA and ETC, we find significant depletion
of genes involved in mitochondrial transport and beta-oxidation of fatty acids, i.e., cytosolic
carnitine palmitoyltranferase (Cpt1a), mitochondrial acyl-synthetases (Acsf2, Accs1, Acss3),
and 2,4 dienoyl-CoA reductase (Decr1), the latter participating in the beta-oxidation of
unsaturated FAs.
Finally, we find increased transcript levels for several ROS-protective enzymes, e.g.,
superoxide dismutase (Sod1), peroxiredoxins (Prdx2, Prdx5), glutathione-S-transferase
(Gstm7), and glutathione peroxidase (Gpx4).
Selected target genes (OXPHOS complex I and complex V components Cox11 and
Atp5s, mitochondrial pyruvate transporter Mpc1, ROS-protector peroxiredoxine Prdx5)
were chosen to validate the RNA-Seq data by RT-qPCR. The differences in gene ex-
pression levels determined by RT-qPCR were consistent with the transcriptome data
(Supplementary Figure S2).
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2.3. Mutation-Related Metabolic Changes in 19-Month-Old Animals
To investigate whether in addition to the transcriptome changes, the mutation V338Y
manifests at the level of metabolic alterations, we performed untargeted metabolomic
profiling in brain cerebellum samples of 19-month-old wild-type and V338Y mutants;
304 metabolites common to all wild-type and mutant samples were identified. After
removing redundant and false positives, 50 metabolites were found to be significantly
altered in V338Y mutants compared to wild-type mice. Most importantly, we found
that TCA intermediates acetyl-CoA, isocitrate, and α-ketoglutarate were significantly
enriched in the V338Y mutants (Table 2). Increased levels of TCA intermediates came
together with an accumulation of intermediates of fatty acid catabolism: oleoylcarnitine,
palmitoylcarnitine, acetylcarnitine, and the carnitine precursor deoxycarnitine. In addition,
we find elevated levels of both forms of glutathione in the V338Y mutant—oxidized (GSSG)
and reduced (GSH) glutathione, with a resulting relative increase in the GSSG/GSH ratio
(ratio GSSG/GSH was 0.51 for wild-type and 0.70 for mutant animals).
Table 2. Selected metabolites with different pool sizes in 19-month-old MRPS5V338Y/V338Y mutant


















ascorbate (Vitamin C) 0.44 0.062
Glutathione metabolism
glutathione, oxidized (GSSG) 1.92 0.003
glutathione, reduced (GSH) 1.39 0.048
Only metabolites with a p-value < 0.1 are shown.
3. Discussion
We have previously shown that brain mitochondria of mice carrying the homozy-
gous knock-in mutation MRPS5 V338Y show impaired mitochondrial function with de-
creased oxygen consumption, reduced ATP content, and increased levels of reactive oxygen
species [11]. Presumably, impaired mitochondrial function in these mice is the result of
less functional mitochondrial OXOHOS proteins synthesized on mistranslating V338Y mi-
toribosomes. We here used whole genome transcriptome analysis together with metabolic
studies to further profile the molecular alterations associated with mitochondrial misread-
ing. Our data indicate a concerted transcriptional and metabolic response to mitigate
impaired functionality of OXPHOS complexes (see Figure 3). This response includes (i)
elevated gene transcripts of nuclear-encoded components of OXPHOS complexes; (ii)
transcriptional upregulation of glycolysis and TCA providing NADH and FADH2 to fuel
oxidative phosphorylation; and (iii) increased transcript levels of ROS-protective enzymes.
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As a result of increased glycolysis, elevated levels of pyruvate and NADH can either
be converted to lactate and NAD+ by lactate dehydrogenase or transported into mito-
chondria for further utilization in the TCA. Together with transcriptional upregulation of
glycolytic enzymes, mutant V338Y mice show increased transcript levels of both lactate
dehydrogenase (Ldhb) and pyruvate transporters MPC1/MPC2 combined with compo-
nents of the malate-aspartate shuttle involved in NADH transport (Mdh1, Got2, Slc25a12).
Inside mitochondria, pyruvate can enter the TCA either as oxaloacetate (increased levels of
pyruvate carboxylase Pcx) or as acetyl-CoA (increased levels of pyruvate-dehydrogenase
complex Dlat and Dld and positive regulator Pdp1). Transcriptional upregulation of Gls2
and Got2 points to additional anaplerotic replenishment of the TCA cycle by 2-ketoglutarate.
Together with more active glycolysis, pyruvate/NADH transport, and anaplerotic replen-
ishment, transcriptional upregulation of the TCA cycle leads to enhanced mitochondrial
NADH levels. However, the functional impairment of oxidative phosphorylation in the
brain of MRPS5 V338Y mutant mice, as indicated by reduced levels of total oxygen con-
sumption, would hinder the effective oxidation of extra NADH, thus slowing down TCA
reactions and leading to an accumulation of TCA intermediates (isocitrate, 2-ketoglutarate)
and substrate acetyl-CoA. Supporting this finding, we note increased levels of the TCA
side-product 2-hydroxyglutarate (fold change 1.71, p-value 0.123), which is a marker of
mitochondrial reductive stress caused by respiratory chain dysfunction [17]. In contrast to
isocitrate and α-ketoglutarate, there is no significant difference for citrate in V338Y mutants
compared to wild-type (fold change 0.99, p-value 0.85). Interconversion of citrate and
isocitrate is necessary for the TCA cycle to operate in either direction. Changes in this
equilibrium with elevated levels of isocitrate or perturbations that result in an increase
in the α-ketoglutarate/citrate ratio, as both observed in the V338Y mutants, would favor
reductive metabolism [18]. Reductive flux via the TCA cycle culminates in the export of
mitochondrial citrate into the cytosol and conversion to cytosolic acetyl-CoA and further to
malonyl-CoA via ATP citrate lyase and acetyl-CoA carboxylase (increased levels for Acly
and Acacb are found in the V338Y mutants).
We observed significant changes in brain fatty acid (FA) metabolism of MRPS5 V338Y
mutant mice both at the transcriptomic and metabolomic level. While the brain’s capacity
for FA oxidation is limited [19], astrocytes can in part use FA oxidation to support their
energetic demands [20]. In brain of MRPS5 mutant mice, accumulation of FA-catabolic
intermediates oleoylcarnitine, palmitoylcarnitine, butyrylcarnitine (p-value 0.118), acetyl-
carnitine, and carnitine precursor deoxycarnitine comes together with decreased transcript
levels of genes and enzymes responsible for transport of FAs into mitochondria and sub-
sequent β-oxidation (Cpt1a, Acsf2, Acss1, Acss3, Decr1). Inhibition of FA-oxidation has
been observed as a result of impaired oxidative phosphorylation [21]. Presumably, under
conditions of less effective OXPHOS, glycolysis is favored over FA-oxidation for ATP
generation, as compared to glycolysis FA-oxidation requires higher oxygen consumption.
With interest, we note that skeletal muscle and brain, sampled in parallel from the
identical cohorts of MRPS5V338Y/V338Y mutant mice, despite sharing the characteristic
of postmitotic tissue, show disparate responses to impaired function of the 13 mtDNA
encoded OXPHOS proteins. While for both tissues the effect of the MRPS5 V338Y mutation
is age-dependent, we find bypassing of ETC by increased glycolysis, pentose phosphate
pathway, fatty acid synthesis, and generation of lipid droplets in muscle [22], compared
to increased flow through TCA and ETC in brain. Presumably, the latter reflects the
dependency of neuronal cells on energy production via glycolysis feeding into TCA and
ATP generation by oxidative phosphorylation. Dichotomic responses to disruption of
oxidative phosphorylation have also been observed in C. elegans with compensation either
by increasing ETC activity and feeding more substrates into the TCA cycle, or by bypassing
ETC and upregulation of glycolysis, glyoxylate cycle, and glycerol fermentation [23].
Most prominent in aging is the decline of mitochondria-related energy production [15,16].
The significant upregulation of transcripts related to mitochondrial metabolism in V338Y
mutant mice, e.g., oxidative phosphorylation, glycolysis, and TCA cycle, reflects a compen-
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satory response, which even at the level of individual pathway-specific genes mitigates
their age-related decline (Supplementary Table S2). We note that this comes along with less
pronounced enrichment of age-associated gene expression related to extracellular matrix
and inflammation in the V338Y mutants (Supplementary Table S3). We hypothesize that
the transcriptomic alterations observed in brain of the 19-month-old V338Y mutant animals
are part of a mitohormetic response [24–26] to the mildly impaired function of the mtDNA
encoded OXPHOS proteins generated by mistranslating mitoribosomes.
4. Materials and Methods
4.1. Animals
The transgenic MRPS5V338Y/V338Y mouse strain has been previously described [11].
Animal experiments were approved by the Veterinary Office of the Canton of Zurich
(licenses 29/2012 and 44/2015).
Expression levels of MRPS5 mRNA were comparable in the brain of mutant and
wild-type mice, indicating that the mutation did not lead to deregulation of MRPS5 gene
expression. The animals were sacrificed at three and 19 months of age; the brain was
carefully isolated, split to cortex and cerebellum, snap frozen, and stored at −80 ◦C.
4.2. RNA Extraction
The following mice were used for the analysis: four three-month-old female ani-
mals of MRPS5WT/WT, four three-month-old female animals of MRPS5V338Y/V338Y, four
19-month-old female animals of MRPS5WT/WT, and four 19-month-old female animals of
MRPS5V338Y/V338Y. Deep frozen cortex was grinded under liquid nitrogen, and RNA was
extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. The quality of the isolated RNA was assessed using a Tapestation 2200
(Agilent Technologies, Santa Clara, CA, USA). Only those samples with a 260/280 nm ratio
between 1.8–2.1 and a 28S/18S ratio within 1.5–2 were further processed; all samples used
for RNA sequencing had RIN (RNA Integrity Number) ≥ 7.5.
4.3. cDNA Library Preparation and Sequencing
RNA sequencing (RNA-Seq) was performed at the UZH/ETH Functional Genomics
Center Zurich (FGCZ) according to the Illumina RNA sequencing protocol. The TruSeq
Stranded mRNA Sample Prep Kit (Illumina, San Diego, CA, USA) was used in the suc-
ceeding steps. Briefly, total RNA samples (100–1000 ng) were ribosome depleted and
then reverse-transcribed into double-stranded cDNA with actinomycin added during first-
strand synthesis. The cDNA samples were fragmented, end-repaired, and polyadenylated.
TruSeq adapters containing the index for multiplexing were ligated to the fragmented DNA
samples. Fragments containing TruSeq adapters on both ends were selectively enriched
with PCR. The quality and quantity of the enriched libraries were validated using Qubit®
(1.0) Fluorometer and the Caliper GX LabChip® GX (Caliper Life Sciences, Hopkinton,
MA, USA). The product was a smear with an average fragment size of approximately
360 bp. The libraries were normalized to 10 nM in Tris-Cl 10 mM, pH 8.5, with 0.1% Tween
20. The TruSeq SR Cluster Kit v4-cBot-HS (Illumina, San Diego, CA, USA) was used for
cluster generation using 8 pM of pooled normalized libraries on the cBOT. Sequencing was
performed on the Illumina HiSeq 2500 single end 126 bp using the TruSeq SBS Kit v4-HS
(Illumina, San Diego, CA, USA).
4.4. Transcriptome Data Analysis
The quality of the reads was assessed using FastQC (Babraham Bioinformatics
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ accessed on 8 January 2017),
and potential contaminations were evaluated with FastQ Screen (Babraham Bioinformatics
(http://www.bioinformatics.babraham.ac.uk/projects/fastq_screen/ accessed on 8 Jan-
uary 2017) using bowtie2 vs. 2.1.0 [27] default parameters. Quantification of gene expres-
sion was performed using the RSEM package (version 1.2.18) [28] mapping against the
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Ensembl 75 annotations derived from the mouse genome assembly GRCm37. Genes not
present (<10 counts per gene) in at least 50% of samples from one condition were discarded
from further analyses. Differential gene expression analysis between sample groups of
interest was performed using the R/bioconductor package edgeR [29]. Differences in gene
expression levels were calculated as log2 fold changes; resulting p-values were adjusted
using Benjamini–Hochberg multiple test correction [30]. An adjusted p-value < 0.05 (for
comparison 19-month-old WT vs. V338Y mutant samples) and <0.00001 (for compari-
son 19-month-old vs. three-month-old WT or V338Y mutant samples) was considered
statistically significant; no fold change threshold was applied.
BGA analysis was done using R/bioconductor package MADE4 [31]. Genes used for
this analysis included all genes with adjusted p-values < 0.05 (for comparison 19-month-
old WT vs. three-month-old WT and 19-month-old V338Y mutant vs. three-month-old
V338Y mutant).
Functional annotation of differentially expressed genes and pathway enrichment
analysis was performed using the online biological information tool EnrichR (http://amp.
pharm.mssm.edu/Enrichr/ accessed on 8 June 2020) [12] that integrates several biologi-
cal databases and provides a comprehensive set of functional annotation information on
genes and proteins. The databases KEGG (Kyoto Encyclopedia of Genes and Genomes,
http://www.genome.jp/kegg/pathway.html accessed on 8 June 2020) [32], WP (WikiPath-
ways, https://www.wikipathways.org accessed on 8 June 2020) [33], and GO (Gene Ontol-
ogy enrichment, http://www.geneontology.org accessed on 8 June 2020) [34] from EnrichR
were used for analysis. In addition, Process Networks analysis was done using the online
tool MetaCore (Clarivate Analytics, Philadelphia, PA, USA, https://portal.genego.com/ ac-
cessed on 8 June 2020). The Benjamini–Hochberg false discovery rate (FDR) procedure was
applied to pathway analysis as a correction for multiple testing. Pathways or terms with
FDR corrected p-value (adjusted p-value) < 0.05 were considered statistically significant.
4.5. qRT-PCR
To confirm the results of transcriptome analysis, selected genes were subjected to
qRT-PCR (for list of genes and primers see Supplementary Table S4). RNA samples were
reverse transcribed into cDNA using High Capacity RNA-to-DNA Kit (Applied Biosystems,
Foster City, CA, USA). cDNA was analyzed by real-time quantitative PCR (qPCR) using an
ABI 7500 Fast Real Time PCR system (Applied Biosystems, Foster City, CA, USA) and a
pair of gene-specific primers for each selected gene. qPCR was performed in triplicates
using EvaGreen Mix (Bio&SELL, Feucht, Germany) and 20 ng of cDNA per reaction. The
transcript levels were normalized to the geometric mean of three housekeeping genes
(Hmbs, Ywhaz, Actb) [35,36] from the same sample used as an internal reference, and the
fold change of mutant relative to the WT mice was calculated as 2−∆∆CT [37]. Statistical
analysis was performed with GraphPad Prism 5.0 software; unpaired Student’s t-test was
used to estimate significance.
4.6. Metabolome Analysis
Cerebellums isolated from ten 19-month-old female animals of MRPS5WT/WT and five
19-month-old female animals of MRPS5V338Y/V338Y were used for metabolome analysis.
Metabolome analysis was performed by Metabolon (Morrisville, NC, USA). In brief, sam-
ples were prepared by proprietary series of organic and aqueous extractions in order to
remove proteins and to recover maximum amount of small molecules. The extracted sam-
ples were split in equal parts and analyzed via GC-MS or LC-MS/MS. For the LC-MS/MS
two equal parts were analyzed in the positive (acidic solvent) and in the negative (basic
solvent) ionization mode. Samples for GCMS were bistrimethyl-silyl-trifluoroacetamide
derivatized and were run with a 5% diphenyl/95% dimethyl polysiloxane fused silica col-
umn. Obtained data were combined and normalized. Welch’s t-test with Holm–Bonferroni
correction was used for statistical analysis.
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4.7. Database Submission
Transcriptome data are available in Gene Expression Omnibus (GEO), accession
number GSE121395, token mbitkoqatfufdkn.
Complete original metabolome dataset is included in Supplementary Data (Supple-
mentary Table S5).
Supplementary Materials: The following are available online at https://www.mdpi.com/1422-0
067/22/5/2746/s1, Figure S1: Brain RNAseq analysis of Mrps5WT/WT and Mrps5V338Y/V338Y mice of
3 months and 19 months age. Figure S2: RT-qPCR for selected genes in brain of MRPS5V338Y/V338Y
and MRPS5WT/WT mice of 19 months age. Table S1: RNA-Seq analysis of MRPS5WT/WT and
MRPS5V338Y/V338Y brain from mice 3 months and 19 months of age. Table S2: Individual genes
related to mitochondria-associated metabolism, differently expressed in brain of 19 months old
MRPS5WT/WT mice in comparison to 3 months old MRPS5WT/WT mice. Table S3: Gene enrichment
analysis comparing 19 months old MRPS5WT/WT and MRPS5V338Y/V338Y mice. Table S4: Primers used
for real-time quantitative PCR of target and house-keeping genes. Table S5: Metabolomic analysis of
MRPS5WT/WT and MRPS5V338Y/V338Y cerebellum from mice 19 months of age.
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